|  | Number and percentage of patients with the mutation (%) |  | ||
---|---|---|---|---|---|
Mutation | No. examined | Total patients | DNMT3A-mutated patients | DNMT3A-wild patients | P value |
IDH1 | 468 | 4 (0.9) | 1 (2.7) | 3 (0.7) | 0.281 |
IDH2 | 464 | 19 (4.1) | 7 (18.9) | 12 (2.8) | < 0.001 |
ASXL1 | 459 | 108 (23.5) | 5 (13.5) | 103 (24.4) | 0.160 |
EZH2 | 469 | 29 (6.2) | 0 (0.0) | 29 (6.7) | 0.153 |
TET2 | 469 | 61 (13.0) | 7 (18.9) | 54 (12.5) | 0.304 |
FLT3/ITD | 465 | 5 (1.1) | 0 (0) | 5 (1.2) | > 0.999 |
JAK2 | 467 | 4 (0.9) | 0 (0.0) | 4 (0.9) | > 0.999 |
NRAS | 469 | 25 (5.3) | 2 (5.4) | 23 (5.3) | > 0.999 |
KRAS | 465 | 8 (1.7) | 1 (2.7) | 7 (1.6) | 0.488 |
PTPN11 | 119 | 1 (0.8) | 0 (0) | 1 (1.0) | > 0.999 |
WT1 | 256 | 1 (0.4) | 0 (0) | 1 (0.4) | > 0.999 |
MLL/PTD | 447 | 5 (1.1) | 2 (5.4) | 3 (0.7) | 0.057 |
RUNX1 | 462 | 61 (13.2) | 7 (18.9) | 54 (12.7) | 0.308 |
U2AF1 | 469 | 35 (7.5) | 2 (5.4) | 33 (7.6) | > 0.999 |
SRSF2 | 469 | 60 (12.8) | 5 (13.5) | 55 (12.7) | 0.801 |
SF3B1 | 469# | 48 (10.2) | 11 (29.7) | 37 (8.6) | < 0.001 |
 Lower-risk IPSS | 249 | 33 (13.3) | 7 (46.7) | 26 (11.1) | 0.001 |
 Higher-risk IPSS | 188 | 11 (5.9) | 3 (15) | 8 (4.8) | 0.098 |
SETBP1 | 466 | 15 (3.2) | 0 (0) | 15 (3.5) | 0.621 |
TP53 | 465 | 42 (9.0) | 4 (10.8) | 38 (8.9) | 0.763 |